论文部分内容阅读
目的探讨新辅助化疗在局部晚期肺癌治疗中的临床疗效。方法将2011年7月-2013年7月我院局部晚期肺癌患者60例随机分为两组各30例,对照组给予肺癌扩大切除术,观察组给予新辅助化疗联合手术治疗,比较两组临床疗效及毒副反应。结果观察组总有效率(CR+PR)高于对照组(P<0.05);观察组化疗51个疗程。发生胃肠道反应14例,骨髓抑制10例,轻度血小板减少6例,粒细胞减少6例。结论新辅助化疗联合手术治疗局部晚期肺癌效果显著,可减少手术切除范围及术后并发症,提高手术切除率,且毒副反应较轻,值得临床推广。
Objective To investigate the clinical efficacy of neoadjuvant chemotherapy in the treatment of locally advanced lung cancer. Methods From July 2011 to July 2013, 60 patients with locally advanced lung cancer in our hospital were randomly divided into two groups of 30 patients. The control group was given extended lung cancer resection, and the observation group was given neoadjuvant chemotherapy combined with surgical treatment. Efficacy and toxicity. Results The total effective rate (CR+PR) of the observation group was higher than that of the control group (P<0.05). The observation group received 51 courses of chemotherapy. Gastrointestinal reactions occurred in 14 cases, bone marrow suppression in 10 cases, mild thrombocytopenia in 6 cases, and neutropenia in 6 cases. Conclusions The neoadjuvant chemotherapy combined with surgical treatment of locally advanced lung cancer has a significant effect, which can reduce the scope of surgical resection and postoperative complications, improve the surgical resection rate, and less toxic side effects, and is worthy of clinical promotion.